OCEA vs. CKPT, BLRX, CALC, ELDN, IMRX, GANX, RPHM, JAGX, KRON, and NBRV
Should you be buying Ocean Biomedical stock or one of its competitors? The main competitors of Ocean Biomedical include Checkpoint Therapeutics (CKPT), BioLineRx (BLRX), CalciMedica (CALC), Eledon Pharmaceuticals (ELDN), Immuneering (IMRX), Gain Therapeutics (GANX), Reneo Pharmaceuticals (RPHM), Jaguar Health (JAGX), Kronos Bio (KRON), and Nabriva Therapeutics (NBRV). These companies are all part of the "pharmaceutical preparations" industry.
Ocean Biomedical (NASDAQ:OCEA) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, community ranking, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.
Ocean Biomedical has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500.
Ocean Biomedical currently has a consensus price target of $17.63, suggesting a potential upside of 1,159.29%. Checkpoint Therapeutics has a consensus price target of $22.60, suggesting a potential upside of 1,525.90%. Given Checkpoint Therapeutics' higher possible upside, analysts clearly believe Checkpoint Therapeutics is more favorable than Ocean Biomedical.
Checkpoint Therapeutics received 166 more outperform votes than Ocean Biomedical when rated by MarketBeat users. However, 100.00% of users gave Ocean Biomedical an outperform vote while only 66.15% of users gave Checkpoint Therapeutics an outperform vote.
24.6% of Ocean Biomedical shares are owned by institutional investors. Comparatively, 22.0% of Checkpoint Therapeutics shares are owned by institutional investors. 73.5% of Ocean Biomedical shares are owned by company insiders. Comparatively, 2.1% of Checkpoint Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Ocean Biomedical has higher earnings, but lower revenue than Checkpoint Therapeutics.
In the previous week, Checkpoint Therapeutics had 5 more articles in the media than Ocean Biomedical. MarketBeat recorded 9 mentions for Checkpoint Therapeutics and 4 mentions for Ocean Biomedical. Checkpoint Therapeutics' average media sentiment score of 0.12 beat Ocean Biomedical's score of 0.00 indicating that Checkpoint Therapeutics is being referred to more favorably in the news media.
Ocean Biomedical has a net margin of 0.00% compared to Checkpoint Therapeutics' net margin of -50,336.89%.
Summary
Ocean Biomedical beats Checkpoint Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Ocean Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCEA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ocean Biomedical Competitors List
Related Companies and Tools
